Where Clinical Data, Science & Evidence Transforms Women’s Health
Stella Vnook
Executive Chair and CEO Kaida Biopharma
Dr. Stella Vnook is a biotech executive, founder, and investor with over 25 years of experience spanning pharmaceuticals, biotechnology, and healthcare commercialization. Dr. Vnook currently serves as Executive Chair and CEO of Kaida Biopharma, a women's oncology company advancing novel hormone-based therapies, with a lead focus on ovarian cancer, followed by expansion into endometrial and triple-negative breast cancers. Dr. Vnook is also the Founder and President of Oral BioLife, Inc., a regenerative medicine company advancing treatments for periodontal disease, and the Founder of ACG Corporate Architects™, where she builds and scales healthcare and life sciences companies. In addition, Dr. Vnook leads Aviva Ventures, an investment and venture platform focused on supporting and scaling innovative healthcare companies. Throughout her career, Dr. Vnook has led both early-stage and growth-stage organizations, with a focus on translating scientific innovation into commercially viable products across oncology, cell therapy, neuroscience, and diagnostics. Dr. Vnook is recognized for expertise in company formation, clinical strategy, and commercialization, and is a frequent speaker on healthcare innovation and the future of personalized medicine.
Day Two - Friday, December 4, 2026
2:30 PM Panel: Why Chronic Disease Looks Different in Women and How Health Systems Have Adapted
- Overview of chronic diseases with female predominance.
- Focus on the science/biology behind the female predominance of autoimmune disorders.
- Health inequities women face in chronic disease, with a case study on lupus.
- How delayed diagnosis, unequal access to specialist care, gaps in research funding, and limited awareness of sex specific disease presentation have led to poorer outcomes for women living with lupus, particularly women from marginalized communities
- How we can advocate for a shift toward personalized coverage models, ensuring that if a treatment is proven effective for a specific subset of women (based on genetics, hormonal stage, or background), reimbursement frameworks evolve to support targeted access rather than applying a one-size-fits-all approach.
Check out the incredible speaker line-up to see who will be joining Stella.
Download The Latest Agenda
